4547.T Stock - Kissei Pharmaceutical Co., Ltd.
Unlock GoAI Insights for 4547.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $88.33B | $75.58B | $67.49B | $65.38B | $69.04B |
| Gross Profit | $44.06B | $37.34B | $32.38B | $31.24B | $32.72B |
| Gross Margin | 49.9% | 49.4% | 48.0% | 47.8% | 47.4% |
| Operating Income | $5.77B | $4.02B | $-1,129,000,000 | $-1,402,000,000 | $1.50B |
| Net Income | $11.96B | $11.16B | $10.53B | $12.92B | $5.29B |
| Net Margin | 13.5% | 14.8% | 15.6% | 19.8% | 7.7% |
| EPS | $274.20 | $246.58 | $228.30 | $280.19 | $113.25 |
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
Visit WebsiteEarnings History & Surprises
4547.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Jan 30, 2026 | — | — | — | — |
Q4 2025 | Nov 4, 2025 | $73.59 | $78.79 | +7.1% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $62.32 | $72.91 | +17.0% | ✓ BEAT |
Q1 2025 | Feb 3, 2025 | $85.02 | $82.99 | -2.4% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $58.80 | $25.86 | -56.0% | ✗ MISS |
Q3 2024 | Jul 30, 2024 | $58.80 | $92.89 | +58.0% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $110.76 | $63.78 | -42.4% | ✗ MISS |
Q1 2024 | Jan 30, 2024 | $53.67 | $59.18 | +10.3% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $51.41 | $52.66 | +2.4% | ✓ BEAT |
Q3 2023 | Jul 31, 2023 | $56.20 | $70.95 | +26.2% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $135.00 | $83.72 | -38.0% | ✗ MISS |
Q1 2023 | Jan 31, 2023 | $19.00 | $72.45 | +281.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $24.00 | $36.67 | +52.8% | ✓ BEAT |
Q3 2022 | Aug 1, 2022 | $44.25 | $35.47 | -19.8% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-32.00 | $132.32 | +513.5% | ✓ BEAT |
Q1 2022 | Feb 1, 2022 | $4.00 | $25.00 | +525.0% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $32.00 | $43.85 | +37.0% | ✓ BEAT |
Q3 2021 | Aug 2, 2021 | $2.00 | $79.02 | +3851.0% | ✓ BEAT |
Q2 2021 | May 11, 2021 | — | $-24.83 | — | — |
Latest News
Frequently Asked Questions about 4547.T
What is 4547.T's current stock price?
What is the analyst price target for 4547.T?
What sector is Kissei Pharmaceutical Co., Ltd. in?
What is 4547.T's market cap?
Does 4547.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4547.T for comparison